// App-Quantinova.ai

4657 : Dose Adjustment and Use of Alternative Eltrombopag Dosing Regimens for the Treatment of Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Researchers

Presenter

  • Panagiotis Bacarakos

Principal Investigators

  • Dimitris Tsokanas

  • Ilias Minakakis

  • Zoi Topouzoglou

  • Georgia Leveta

  • Theodore Marinakis

  • Christina Papadaki

  • Vasiliki Grigoraki

  • Elpiniki Griva-Kritikou

  • Anagnostopoulos I. Nikolaos

Medical Centers

  • Laboratory Hematology, G.Gennimatas General Hospital

  • Clinical Hematology, G.Gennimatas General Hospital

  • Clinical Hematology, G.Gennimatas General Hospital

  • Clinical Hematology, G.Gennimatas General Hospital, Athens, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Eltrombopag

  • Romiplostim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved